secwatch.observer — SEC 8-K summary
======================================

Issuer:     Barinthus Biotherapeutics plc. (BRNS)
CIK:        0001828185
Form:       8-K
Filed at:   2026-08-25T10:01:24+00:00
Accession:  0001104659-26-100470
Event type: m_and_a
Sentiment:  neutral
Materiality: 0.85
Item codes: 3.01, 7.01, 8.01, 9.01
LLM model:  deepseek-v4-flash:cloud@v2

Barinthus Bio sets scheme exchange ratio at 0.111; merger with Clywedog to close Sept 3
--------------------------------------------------------------------------------

- Scheme exchange ratio set at 0.111, ensuring Topco stock price meets Nasdaq minimum listing requirement.
- Scheme expected effective Sept 3, 2026; BRNS ADSs to halt trading before market open that day.
- Court hearing for scheme set for Sept 1, 2026 at Royal Courts of Justice, London.
- After close, Topco renamed Clywedog Therapeutics Holdings, Inc., trading as CLYD on Nasdaq.
- Company to delist ADSs from Nasdaq and file Form 15 to suspend reporting obligations.

Source:
  EDGAR index:    https://www.sec.gov/Archives/edgar/data/1828185/000110465926100470/0001104659-26-100470-index.htm
  Primary doc:    https://www.sec.gov/Archives/edgar/data/1828185/000110465926100470/tm2623930d1_8k.htm
  HTML page:      https://secwatch.observer/filing/0001104659-26-100470

License: Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer